UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000037150
Receipt number R000042336
Scientific Title Examination of efficacy and safety treated by Mirogabalin in patients with peripheral neuropathy in Orthopaedic disease
Date of disclosure of the study information 2019/06/25
Last modified on 2019/06/24 16:55:14

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Examination of efficacy and safety treated by Mirogabalin in patients with peripheral neuropathy in Orthopaedic disease

Acronym

Examination of efficacy and safety treated by Mirogabalin in patients with peripheral neuropathy in Orthopaedic disease

Scientific Title

Examination of efficacy and safety treated by Mirogabalin in patients with peripheral neuropathy in Orthopaedic disease

Scientific Title:Acronym

Examination of efficacy and safety treated by Mirogabalin in patients with peripheral neuropathy in Orthopaedic disease

Region

Japan


Condition

Condition

Patients with peripheral neuropathy in Orthopaedic diseases

Classification by specialty

Orthopedics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The aim of this study is to examine the efficacy and safety treated by Mirogabalin in patients with peripheral neuropathy in Orthopaedic diseases for 6 months

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Percent changes from the baseline values prior to treatment

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -but assessor(s) are blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Mirogabalin group

Interventions/Control_2

Pregabalin group

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

100 years-old >=

Gender

Male and Female

Key inclusion criteria

1 More than 40mm of VAS or 40 points of NRS in patients with peripheral neuropathy
2 Patients who agree with this study

Key exclusion criteria

1 Patients who have taken Mirogabalin or Prerogabalin before
2 Patients who are allergic to Mirogabalin or Prerogabalin
3 Others

Target sample size

60


Research contact person

Name of lead principal investigator

1st name Yukio
Middle name
Last name Nakamura

Organization

Shinshu University School of Medicine

Division name

Dept. of Orthopaedic Surgery

Zip code

3908621

Address

Asahi 3-1-1, Matsumoto 3908621, Japan

TEL

0263372659

Email

yxn14@aol.jp


Public contact

Name of contact person

1st name Yukio
Middle name
Last name Nakamura

Organization

Shinshu University School of Medicine

Division name

Dept. of Orthopaedic Surgery

Zip code

3908621

Address

Asahi 3-1-1, Matsumoto 3908621, Japan

TEL

0263372659

Homepage URL


Email

yxn14@aol.jp


Sponsor or person

Institute

Dept. of Orthopaedic Surgery
Shinshu University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Shinshu University School of Medicine

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Shinshu University School of Medicine

Address

Asahi 3-1-1, Matsumoto 3908621, japan

Tel

0263-37-2572

Email

mdrinri@shinshu-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 06 Month 25 Day


Related information

URL releasing protocol


Publication of results

Partially published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2019 Year 06 Month 17 Day

Date of IRB

2019 Year 06 Month 04 Day

Anticipated trial start date

2019 Year 06 Month 25 Day

Last follow-up date

2024 Year 06 Month 24 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 06 Month 24 Day

Last modified on

2019 Year 06 Month 24 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042336


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name